Was this a RCT?
Although a range of study designs can be used to assess the effects of treatments, a RCT provides the most trustworthy (valid) evidence of effectiveness of treatments compared with other study designs.
In a RCT one group receives the treatment being tested, whilst a comparison group receives an alternative treatment. The key is that the likelihood of each participant receiving the trial treatment is determined by chance (random allocation). A broad range of health care interventions can be tested in RCTs, such as specific
Screening questions
l Did the study ask a clearly focused question? l Was this a randomised controlled trial (RCT) and was it appropriately so? If the answer is 'Yes' to both, it is worth proceeding with the remaining questions.
Validity (trustworthiness)
Were participants appropriately allocated to intervention and control groups? l Were participants, staff, and study personnel 'blind' to participants' study group? l Were all of the participants who entered the trial accounted for at its conclusion?
l Were the participants in all groups followed up and data collected in the same way? Applying the study findings l Were all the important outcomes considered so the results can be applied? therapies (e.g. drug therapy, counselling) or broader clinical policies (e.g. screening). The alternative intervention may include the standard treatment, a placebo or no treatment. Comparing the outcomes in the different groups allows an assessment of the results of the trial. Unlike the dramatic therapeutic benefits observed with the introduction of penicillin or insulin, most effective treatments tend to have modest but important benefits. 5 Rigorous research methods that employ a carefully designed RCT are required to reliably detect such effects. For a RCT to be ethical and feasible to conduct, genuine uncertainty that a treatment works is essential. Treatments are sometimes advocated on the grounds of prevailing theory, or even 'common sense.' For example, the reported beneficial effects of hormone replacement therapy (HRT) on lipids -a proxy measure for coronary heart disease (CHD) risk -do not necessarily translate into a reduction in CHD events. 6 Sometimes RCTs are prohibitively difficult or inappropriate to conduct. This is especially so when we hope to detect small differences or improvements for relatively rare outcomes, such as venous thromboembolism. In such cases, evidence about the benefits and risks of treatments might be required from large cohort or case-control studies. Such non-randomised studies, however, tend to show larger (or even falsepositive) treatment effects compared with RCTs. 7 When these once-promising effect sizes are put to the sword of randomised evaluations they tend to diminish, sometimes altogether. For example, the reduction in the risk of CHD suggested by observational studies of HRT has not been confirmed by RCTs. [8] [9] [10] Judging validity Questions about validity are concerned with how trustworthy study findings are, based on the details of how the trial was conducted reported in a paper's methods section. Just as a designer label does not guarantee quality, the use of 'randomisation' in a study does not guarantee bias-free results. Attention needs to be paid to the adequacy of the randomisation process and the levels of care and attention subsequently received by study participants. Poorer quality randomised trials produce results that tend to overestimate the benefits of treatments compared with well-conducted trials. 7 Were participants appropriately allocated to intervention and control groups? In the DSG study, women were randomly allocated in a ratio of 3:1 (resulting in a DSG group of 989 and an LNG group of 331 women), presumably to provide more reliable follow-up data for women on DSG.
True randomisation usually entails allocating participants on the basis of computer-generated lists of random numbers. Quasi-randomisation involves allocating participants to study and control groups in a predictable manner (e.g. according to date of birth). The problem with predictable allocation is that prior knowledge of the allocation sequence might influence when and whether a clinician recruits participants. Clinicians naturally might wish to ensure that their patients receive what they judge to be the best treatment. This can lead to those patients with the most (or sometimes least) favourable prognoses receiving the study treatment.
Safeguards also need to be built into the process of trial entry. The use of sealed envelopes containing randomly generated treatment allocations is prone to tampering; clinicians may continue opening envelopes until the preferred treatment for a particular patient is found. Remote allocation, whereby the clinician contacts a centre 'hotline' by telephone or via an Internet website to ascertain the patient's allocation status following consent, can assure the independence of randomisation.
How women were randomly allocated in the DSG trial is not adequately described. No details are provided concerning how the random allocation schedule was created, concealed or administered. However, the baseline characteristics of the groups (age, menstrual patterns and previous pregnancies) following randomisation were similar, suggesting that the trial's randomisation process successfully produced two comparable groups.
In a carefully conducted RCT, the treatment allocation is made after trial entry has been decided upon. This sequence ensures that foreknowledge of what the next treatment is going to be cannot affect the decision to enter the participant into the trial. If it did, those allocated one treatment might differ systematically from those allocated another. For example, if a trial selectively recruited more highly motivated women to one group rather than another, subsequent pregnancy rates may differ because of this. Random allocation is intended to distribute such potential confounding factors evenly across the two groups. Any differences in outcome are therefore more likely to be attributable to the treatment alone rather than the characteristics of women allocated to each group. Some imbalance in confounding factors between the treatment and control groups can still occur by chance, although this becomes less likely with larger clinical trials.
This 'methodological paranoia' is based upon strong empirical evidence as well as confidential confessions of trial clinicians. 11, 12 Quasi-randomisation and less rigorous methods of allocating treatments are associated with inflated estimates of treatment effects. 7 The randomisation and allocation processes are not fully described in the DSG study. The lack of a clear description of the allocation processes in research papers is itself associated with inflated estimates of the effects of treatment. 12 Were participants, staff and study personnel 'blind' to participants' study group? The trial was 'double-blind' in that the women recruited and the clinicians providing care did not know who had been allocated to which treatment, as participants received 'identical-looking tablets'. Expectations of the effect of a treatment can influence outcomes. For example, a woman who knew she had been allocated to the latest POP might behave differently, possibly becoming less (or even more) reliable in taking her pill regularly. She might have greater expectations of the treatment and hence discount or not report adverse effects. Similarly, clinician knowledge of a participant's treatment status may influence the level of additional support provided ('performance bias') or the recognition and recording of harms and benefits ('observation bias'). Concealing which group the patient is allocated to (blinding or masking) reduces such biases and can be applied to patients, clinicians or investigators. Blinding is not always feasible for treatments with known side effects or if the intervention is obvious (e.g. surgery).
Investigators are also prone to observation bias. This is less of a problem with objective outcomes, such as mortality, but it can be problematic for subjective outcomes, such as pain or menstrual bleeding. The trial used standardised criteria for assessing bleeding patterns from women's self-completed diaries, which helps to reduce observational bias.
Were all the participants who entered the trial accounted for at its conclusion?
This is where the real fun usually begins. Adverse events or the ineffectiveness of treatment may cause participants to Evidence-based Reproductive Health group.bmj.com on June 18, 2017 -Published by http://jfprhc.bmj.com/ Downloaded from drop out of a treatment arm. Hence all participants entering a trial should be accounted for at the end of the study. 'Attrition bias' occurs if participants dropping out of one study arm systematically differ from those in the other arm. Their exclusion from the final analysis will lead to the overestimation of any true treatment effect. If you are interested in the effectiveness of clinical actions (such as switching POPs), then study participants should be analysed in the group to which they were allocated, even if they do not receive the treatment. This is known as intention-to-treat analysis.
Inevitably, some people drop out of trials following randomisation, and it is sometimes neither feasible nor ethical to continue collecting outcome data. In this trial, 14 randomly allocated women never started DSG or LNG, leaving 979 and 327 in each group, respectively, at the outset. There were considerable losses to follow-up over the 13 months of the clinical trial (40% or more), and the group of women completing the trial are likely to systematically differ from those who entered the trial. There is no hard-and-fast rule on what level of follow-up is acceptable but at least 80% is preferable to reduce the likelihood of major attrition bias. 13 Were the participants in all groups followed up and data collected in the same way? There is therefore nothing to suggest any scope for performance bias, such as more intensive follow-up of those on the study treatment. Follow-up was standardised so that data were collected in the same manner for all women at 3, 7 and 13 months. Participants self-completed diary cards and were questioned on the occurrence of adverse events. How pregnancy was confirmed is not described and it is unclear if miscarriages were included.
Making sense of the results

Did the study have enough participants to minimise the play of chance?
Statistical power is the ability of a clinical trial to detect a difference between groups when a true difference really exists. This study was powered to detect a 7% difference in bleeding between women treated with DSG as opposed to LNG. But it was not powered to detect important differences in pregnancy outcomes. Thus at the outset of the trial any differences found in relation to pregnancy outcomes were likely to be attributable to chance.
How are the results presented and what is the main result?
The presentation in the paper of data on vaginal bleeding patterns is complex and largely restricted to two subgroups (POP 'switchers' and 'starters'). Such subgroup analyses can be misleading and require cautious interpretation. 14 Such analyses need to be stated in advance, relate to the primary outcome measure and be limited in number. When a trial fails to detect a statistically important effect overall (as this trial did) subgroup analysis should not influence the conclusions drawn. 14 For the assessment of the trial primary outcome of bleeding patterns, the discontinuation rate for both POPs over 13 months' follow-up was very high. Overall 44% stopped the POP to which they were originally randomised. Discontinuation due to 'irregular bleeding' was an absolute 4.5% higher in the DSG group than the LNG group (Table  1) . This means that on average for every 23 patients allocated to DSG (instead of LNG), one additional women stopped her POP before 13 months due to bleeding problems. There was little difference between POPs with respect to all adverse events (around 40%), or serious adverse events (around 1.5%).
The secondary outcome of contraceptive efficacy was assessed by the occurrence of pregnancy during the 13 months of the trial 'in-treatment' period. The pregnancy rate from the trial was based on 'women-years' (Table 1) . A woman taking a POP for 6 months would be counted as having contributed 6/13 (or 0.46) women-years over the 13-month follow-up period. The pregnancy rate was low for both groups: 0.41 pregnancies per 100 women taking DSG compared with 1.55 pregnancies per 100 women taking LNG (both averaged for 1 year of POP consumption) ( Table 1 ).
The absolute difference between these two rates is 1.14 per 100 women (this is simply derived by subtracting one from the other). The number of women needed to treat (NNT) in order to avoid one pregnancy is thus 88 (i.e. 100 divided by 1.14, the 'reciprocal of the absolute difference'). Hence the trial indicates that some 88 women need to take DSG for 1 year (instead of LNG) in order to avoid one additional pregnancy (that would occur with LNG).
How precise are these results?
At the outset the trial was powered to detect a 7% difference between the two groups. It was not large enough to confirm that the actual difference found (4.5%) was due to the play of chance finding. The NNTs shown (Table 1) all include 'infinity (¥)', indicating that the results are compatible with there being no real difference between these two POPs. The lower limit of the NNTs puts a lower limit on the assessment of differences between these two POPs. For example, the NNT to prevent pregnancy is unlikely to be better than 29 women taking DSG for 1 year (instead of LNG) to prevent one additional pregnancy. Similarly, the NNT to cause irregular vaginal bleeding is unlikely to be worse than 11 (Table 1) .
Were all the important outcomes considered so the results can be applied? This question is largely concerned with whether you can apply the findings of the study locally. The trial participants represent a selective and more highly motivated group of woman than those seen in routine clinical practice and you therefore might not anticipate equally good Pearl indices in your population. Clearly you would not require any additional equipment or skills (e.g. counselling) in order to change your prescribing of POPs. However, cost inevitably becomes a consideration if you did wish to add it to your Evidence-based Reproductive Health group.bmj.com on June 18, 2017 -Published by http://jfprhc.bmj.com/ Downloaded from repertoire. Based on the current British National Formulary, a year's supply of DSG would cost £115 compared with £9 for LNG. 15 A potentially lower failure rate for DSG would benefit women and result in health care savings which might outweigh the increased prescription costs.
One limitation of the trial was that it did not assess the influence of these POPs on the quality of life of the women in the study. The issue of bleeding patterns is only important insofar as it can affect women's quality of life. A further consideration is the safety of DSG, which has been associated with an increased risk of thromboembolism (pulmonary embolus and deep vein thrombosis) compared with LNG when used in the COC. 16 However, current evidence suggests that POPs are not associated with venous thromboembolism. 17 
